Campbell Newman Asset Management Inc. Acquires 3,054 Shares of Zoetis Inc. (NYSE:ZTS)

Campbell Newman Asset Management Inc. boosted its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 3.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 100,248 shares of the company's stock after buying an additional 3,054 shares during the quarter. Zoetis makes up about 1.4% of Campbell Newman Asset Management Inc.'s holdings, making the stock its 29th largest position. Campbell Newman Asset Management Inc.'s holdings in Zoetis were worth $16,506,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ZTS. Rakuten Securities Inc. grew its holdings in shares of Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after buying an additional 166 shares during the last quarter. Navigoe LLC acquired a new position in shares of Zoetis during the 4th quarter worth approximately $30,000. Murphy & Mullick Capital Management Corp acquired a new position in shares of Zoetis during the 4th quarter worth approximately $44,000. Asset Planning Inc acquired a new position in shares of Zoetis during the 4th quarter worth approximately $58,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new stake in Zoetis in the 4th quarter worth approximately $59,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

ZTS has been the subject of several research reports. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Stifel Nicolaus lowered their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Morgan Stanley reduced their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Finally, Piper Sandler lifted their target price on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Zoetis has an average rating of "Buy" and an average target price of $212.75.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president now directly owns 15,129 shares of the company's stock, valued at $2,571,930. This represents a 4.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.18% of the company's stock.

Zoetis Stock Down 2.7%

ZTS stock traded down $4.55 during midday trading on Friday, reaching $164.27. The company had a trading volume of 2,973,481 shares, compared to its average volume of 2,551,305. The company has a 50 day moving average of $158.67 and a two-hundred day moving average of $164.01. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a market capitalization of $73.13 billion, a P/E ratio of 30.03, a PEG ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same period last year, the business posted $1.38 EPS. Zoetis's revenue was up 1.4% compared to the same quarter last year. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.